Potential liver toxicity in diabetics using Rezulin (troglitazone)

    There's a growing concern about potential liver toxicity in diabetics using Rezulin (troglitazone).

    Rezulin has been given to over half a million patients since it came out early last year.

    But now there are over 150 reports of possible liver dysfunction...resulting in one liver transplant and several deaths.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote